CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
甜蜜生活：用 Glut1 为嵌合抗原受体（CAR）T 细胞供能以提升治疗效果
英文原题：La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy.
查看英文原题
La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法获批用于治疗血液系统恶性肿瘤，标志着癌症治疗进入了一个新时代，自2017年以来已有七款产品获FDA批准。然而，挑战依然存在，尽管在骨髓瘤中最初观察到显著疗效，但大多数患者会复发，这与CAR-T 细胞持久性差相伴随。同样，CAR-T 细胞疗法在实体瘤中的疗效有限，主要归因于肿瘤抗原异质性、免疫逃逸机制以及浸润和持久性差。在这项近期研究中，Guerrero等人致力于通过过表达葡萄糖转运体GLUT1来提高人CAR-T 细胞的疗效，并表明过表达GLUT1的CAR-T 细胞在体内具有更强的持久性和控制肿瘤负荷的能力。
展开英文摘要原文
The approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of hematological cancers has marked a new era in cancer care, with seven products being FDA approved since 2017.
However, challenges remain, and while profound effects are observed initially in myeloma, the majority of patients relapse, which is concomitant with poor CAR T cell persistence. Similarly, the efficacy of CAR T cell therapy is limited in solid tumors, largely due to tumor antigen heterogeneity, immune evasion mechanisms, and poor infiltration and persistence.
In this recent study, Guerrero et al endeavor to improve the efficacy of human CAR T cells by overexpressing the glucose transporter GLUT1 and show that GLUT1 overexpressing CAR T cells have improved capacity to persist and control tumor burden in vivo.
论文信息
- 作者
- Slattery K、Finlay DK、Darcy PK
- 第一作者单位
- School of Medicine, Trinity Translational Medicine Institute, St. James's Hospital, Dublin, Ireland.Ireland
- 通讯作者单位
- Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.Australia
- 期刊
- Immunometabolism (Cobham, Surrey)2025 Jan
- 原文标识
- PubMed 39816133 · DOI 10.1097/IN9.0000000000000055
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →